Associations - Keytruda (pembrolizumab)

PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) pembrolizumab Sensitive : A1 ASCO 2023 - 3d	pembrolizumab Sensitive: A1 - Approval ASCO 2023 - 3 days pembrolizumab Sensitive : A1 ASCO 2023 - 3 days - (New B)
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) pembrolizumab + BCA101 Sensitive : C3 ASCO 2023 - 3d	pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + BCA101 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
RSPO3 fusion	Gastrointestinal Stromal Tumor	RSPO3 fusion	Gastrointestinal Stromal Tumor	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) pembrolizumab + CGX1321 Sensitive : C3 ASCO 2023 - 3d	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + CGX1321 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) pembrolizumab + CUE-101 Sensitive : C3 ASCO 2023 - 3d	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + CUE-101 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days (New C4) pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4d	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4 days - (New C4)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials Immutep Limited Press Release - 1 week (New C3) pembrolizumab + eftilagimod alpha Sensitive : B Immutep Limited Press Release - 1wk	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials Immutep Limited Press Release - 1 week pembrolizumab + eftilagimod alpha Sensitive : B Immutep Limited Press Release - 1 week - (New C3)
MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week (New A2) pembrolizumab Sensitive : A2 NCCN - 1wk	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week pembrolizumab Sensitive : A2 NCCN - 1 week - (New A2)
PD-L1 overexpression	Triple Negative Breast Cancer	PD-L1 overexpression	Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) pembrolizumab Sensitive : B ESMO-BC 2023 - 3wk	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks pembrolizumab Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks (New C4) pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3wk	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3 weeks - (New C4)
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
BRAF E501Q + PD-L1 negative	Lung Adenocarcinoma	BRAF E501Q + PD-L1 negative	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Respirol Case Rep - 3 weeks (New C4) pembrolizumab Sensitive : C4 Respirol Case Rep - 3wk	pembrolizumab Sensitive: C4 – Case Studies Respirol Case Rep - 3 weeks pembrolizumab Sensitive : C4 Respirol Case Rep - 3 weeks - (New C4)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
TMB-H	Solid Tumor	TMB-H	Solid Tumor	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1

Keytruda (pembrolizumab)

Associations
(666)

Associations
(666)

Keytruda (pembrolizumab)

Associations(666)

Associations(666)

Associations
(666)

Associations
(666)